Detection of K14 in Bladder Cancer With a Non Invasive Technique

July 18, 2017 updated by: Juan Francisco Delgado de la Poza, Corporacion Parc Tauli

K14 in Urothelial Cells as a Pronostic and Diagnostic Marker in Bladder Cancer Patients Using a Non Invasive Technique.

By an invasive technique keratin 14 has been identified as a prognostic factor in bladder cancer. This study aims to analyze whether through a non-invasive technique keratin 14 can be used as a diagnostic and prognostic marker for this cancer.

Study Overview

Status

Terminated

Conditions

Bladder Cancer

Study Type

Observational

Enrollment (Actual)

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Spain
- Barcelona
  - Sabadell, Barcelona, Spain, 08208
    - Corporacio Sanitaria i Universitaria Parc Tauli

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Hospital patients.

Description

Inclusion Criteria:

Bladder cancer

Exclusion Criteria:

Inability to sign the informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Observational Models: Case-Control
Time Perspectives: Prospective

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort
Bladder cancer Patients who suffered a bladder cancer
Control group Patients with urologic diseases of non tumoral origin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Keratin 14 Time Frame: At the time of study entry	At the time of study entry

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Corporacion Parc Tauli

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2014

Primary Completion (Actual)

July 1, 2014

Study Completion (Actual)

May 1, 2017

Study Registration Dates

First Submitted

January 3, 2014

First Submitted That Met QC Criteria